Core Viewpoint - Zhaoke Ophthalmology-B (06622) has seen a significant stock price increase, attributed to a distribution and supply agreement with Indonesian pharmaceutical company PT Ferron Par Pharmaceuticals for its core product, atropine eye drops aimed at slowing myopia progression in children and adolescents [1] Group 1: Company Developments - Zhaoke Ophthalmology has signed an exclusive distribution and supply agreement with PT Ferron for the import, promotion, distribution, marketing, and sales of its atropine eye drops in Indonesia [1] - The agreement includes an upfront payment to Zhaoke Ophthalmology, along with potential milestone payments based on certain achievements [1] - Earlier this year, Zhaoke Ophthalmology's applications for the 0.01% and 0.02% formulations of atropine eye drops have been accepted by the National Medical Products Administration of China and are currently under review [1] Group 2: Market Performance - The stock price of Zhaoke Ophthalmology has increased by over 7%, with a current rise of 6.48%, trading at HKD 4.27, and a transaction volume of HKD 10.8763 million [1]
兆科眼科-B再涨超7% 公司与PT Ferron达成战略合作 推动核心产品在印尼商业化